DNDi aims to develop $300-per-course HCV regimen

As part of a newly released R&D strategy to develop a short-course, affordable pan-genotypic HCV therapy for low- and middle-income countries, the Drugs for Neglected Diseases initiative said Pharco Corp. (Alexandria, Egypt) agreed to provide the non-profit with an HCV regimen containing ravidasvir (formerly PPI-668) and Sovaldi sofosbuvir for Phase III trials for less than $300 per course of treatment. The trials are set to start this year.

DNDi said Pharco will also price the regimen commercially at $294 or less per treatment course, if approved. ...